- Home
- LXRX vs ISD Comparison
LXRX vs ISD Comparison
Compare LXRX & ISD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXRX | ISD |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.4M | 488.5M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXRX | ISD |
|---|---|---|
| Price | $1.68 | $13.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.15 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 80.3K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.69% |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $0.32 | $11.82 |
| 52 Week High | $1.83 | $14.79 |
Technical Indicators
Market Signals| Indicator | LXRX | ISD |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 15.27 |
| Support Level | $1.08 | N/A |
| Resistance Level | $1.83 | $14.67 |
| Average True Range (ATR) | 0.13 | 0.18 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 71.62 | 2.76 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About ISD PGIM High Yield Bond Fund Inc.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.